Differential Diagnoses for Nephrotic Syndrome
The differential diagnosis for nephrotic syndrome is divided into primary (idiopathic) glomerular diseases and secondary causes, with membranous nephropathy and focal segmental glomerulosclerosis (FSGS) being the most common primary causes in adults, while minimal change disease predominates in children 1, 2.
Primary (Idiopathic) Glomerular Diseases
The primary glomerular diseases causing nephrotic syndrome include:
- Membranous nephropathy - Most common primary cause in adults, now recognized as an autoimmune disease with pathogenic autoantibodies 1
- Focal segmental glomerulosclerosis (FSGS) - Second most common in adults; must differentiate between FSGS mediated by soluble factors (amenable to immunosuppression) versus FSGS-like histology where immunosuppression should be avoided 1
- Minimal change disease - Predominant cause in children, associated with high steroid-responsiveness 1, 3
- IgA nephropathy - Can present with nephrotic-range proteinuria 4
- Membranoproliferative GN - Now classified under immunoglobulin- and complement-mediated glomerular diseases with an MPGN pattern of injury 1
Secondary Causes
Secondary causes must be systematically ruled out through patient history and targeted diagnostic studies 2. These include:
Systemic Diseases
- Diabetes mellitus - Critical to exclude as it fundamentally changes management 2
- Systemic lupus erythematosus (lupus nephritis) - Requires specific immunosuppressive protocols 1, 2
- Amyloidosis - Though not covered extensively in the KDIGO guideline, remains an important secondary cause 1
Infections
- Hepatitis C-associated immune-complex GN - Often presents with cryoglobulinemic features and membranoproliferative pattern 4
- Infection-related GN - Including IgA-dominant infection-related GN (e.g., S. aureus) 4
- HIV-associated nephropathy
Medications and Toxins
- Drug-induced nephrotic syndrome - Must obtain detailed medication history including NSAIDs, gold, penicillamine, and other nephrotoxic agents 2, 5
Malignancy
- Paraneoplastic glomerular disease - Particularly in older adults with new-onset nephrotic syndrome 5
Other Systemic Conditions
- ANCA-associated vasculitis - Can present with nephrotic-range proteinuria, though typically more nephritic 1, 4
- Anti-GBM antibody disease - Usually presents with rapidly progressive GN but can have nephrotic features 4
- Monoclonal immunoglobulin deposition diseases - Including those associated with Waldenström macroglobulinemia or multiple myeloma 4
Clinical Approach to Narrowing the Differential
The key to narrowing the differential is distinguishing nephrotic from nephritic presentations and identifying red flags for secondary causes 3:
Nephrotic Features (favor primary causes)
- Heavy proteinuria (>3.0 g/24 hours)
- Hypoalbuminemia (<3.0 g/dL)
- Peripheral edema
- Hyperlipidemia
- Minimal hematuria
Nephritic Features (suggest alternative diagnoses)
- Significant hematuria with RBC casts
- Hypertension
- Acute kidney injury
- Lower levels of proteinuria
Red Flags for Secondary Causes
- Age extremes - New nephrotic syndrome in elderly suggests malignancy or amyloidosis
- Systemic symptoms - Fever, rash, arthritis suggest lupus or vasculitis
- Known diabetes - Diabetic nephropathy is the diagnosis until proven otherwise
- Positive serologies - ANA, ANCA, anti-GBM, hepatitis panels
- Extrarenal manifestations - Pulmonary hemorrhage, skin lesions, neuropathy
Important Caveats
A critical pitfall is failing to recognize that cardiac or hepatic disease can mimic nephrotic edema, requiring a high index of suspicion and simple testing (urinalysis for protein and serum albumin) to avoid delayed diagnosis 5.
The KDIGO 2021 guideline emphasizes that renal biopsy is most useful when secondary causes like lupus are suspected, as histology guides both management and prognosis 1, 2. However, in children with typical presentations, steroid responsiveness is the best prognostic marker, not histology 6.
Genetic testing is increasingly important in the differential diagnosis, particularly for steroid-resistant nephrotic syndrome and in patients with APOL1 high-risk genotypes, though specific guidance on incorporating genetic results into treatment algorithms remains limited 7.